Two telehealth companies have formed a national partnership linking menopause and hormone therapy with integrative psychiatry, including screened, off-label at-home ketamine therapy for women whose depression or anxiety has not responded to prior treatment. The model also expands hormone monitoring and preventive care. It reflects a shift toward treating the endocrine and psychiatric features of perimenopause as a single clinical picture rather than separate referrals.
Key Points
- Menopause hormone care and integrative psychiatry delivered through one telehealth pathway
- Screened at-home ketamine offered for treatment-resistant depression and anxiety
- Expanded hormone monitoring supports preventive rather than reactive management
Longevity Analysis
Mood disturbance during the menopausal transition is frequently attributed to psychiatric causes alone, when the underlying driver is a shifting hormonal environment acting on sleep, thermoregulation, and stress reactivity. Reading those signals correctly determines whether a woman receives hormone optimization, psychiatric support, or both — and misattribution costs years of unnecessary symptom burden. Coupling endocrine monitoring with structured psychiatric follow-up and integration coaching moves care from episodic intervention toward sustained, tracked management during a decade that shapes cardiovascular, skeletal, and cognitive trajectory.
Original published by Longevity.Technology.